Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CMMB

Chemomab Therapeutics Ltd ADR

Apr 15 • 04:00PM ET

0.7300

Dollar change -0.0398
Percentage change -5.17	%

Healthcare • Biotechnology • Israel • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.11	Insider Own	16.45%	Shs Outstand	14.20M	Perf Week	-7.67%
Market Cap	10.37M	Forward P/E	-	EPS next Y	-0.07	Insider Trans	0.00%	Shs Float	11.87M	Perf Month	-11.94%
Income	-24.07M	PEG	-	EPS next Q	-0.01	Inst Own	4.06%	Short Float	1.87%	Perf Quarter	30.59%
Sales	0.00M	P/S	-	EPS this Y	41.75%	Inst Trans	-0.73%	Short Ratio	0.97	Perf Half Y	-18.44%
Book/sh	1.20	P/B	0.61	EPS next Y	-25.00%	ROA	-73.83%	Short Interest	0.22M	Perf Year	-53.80%
Cash/sh	1.40	P/C	0.52	EPS next 5Y	-	ROE	-90.46%	52W Range	0.42 - 1.89	Perf YTD	43.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-13.49%	ROI	-139.04%	52W High	-61.38%	Beta	0.37
Dividend TTM	-	Quick Ratio	4.32	Sales past 5Y	0.00%	Gross Margin	-	52W Low	73.81%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	4.32	EPS Y/Y TTM	11.48%	Oper. Margin	0.00%	RSI (14)	44.60	Volatility	4.53% 6.20%
Employees	20	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	7.00
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	62.58%	Payout	-	Rel Volume	0.22	Prev Close	0.77
Sales Surprise	-	EPS Surprise	35.00%	Sales Q/Q	-	Earnings	Mar 07 BMO	Avg Volume	228.80K	Price	0.73
SMA20	-6.12%	SMA50	1.76%	SMA200	-11.98%	Trades		Volume	50,209	Change	-5.17%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-23	Resumed	ROTH MKM	Buy	$7

Apr-02-24 07:00AM	Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 (GlobeNewswire)
Mar-25-24 07:06AM	Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis (GlobeNewswire) -5.60%
Mar-07-24 12:53PM	CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q4 2023 (InvestorPlace) +12.63%
07:00AM	Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update (PR Newswire)
Mar-05-24 07:00AM	Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference (PR Newswire)
07:00AM	Loading…
Feb-20-24 07:00AM	Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases (PR Newswire) +6.37%
Feb-14-24 07:00AM	Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update (PR Newswire)
Feb-05-24 07:00AM	Chemomab Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire) +6.56%
Jan-30-24 07:00AM	Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis (PR Newswire) +7.41%
Jan-03-24 07:00AM	Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 (PR Newswire)
Nov-16-23 07:00AM	Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis (PR Newswire) -19.22%
Nov-15-23 07:00AM	Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis (PR Newswire) +33.93%
Nov-13-23 08:00AM	Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting 2023 (PR Newswire) -6.78%
Nov-09-23 08:00AM	Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update (PR Newswire) -6.10%
Nov-06-23 04:15PM	Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement (PR Newswire) -6.78%
07:00AM	Loading…
Oct-30-23 07:00AM	Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update (PR Newswire) -7.15%
Oct-26-23 07:00AM	Chemomab Therapeutics to Present at Upcoming Scientific Conferences (PR Newswire)
Sep-28-23 07:00AM	Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference (PR Newswire)
Aug-29-23 07:00AM	Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-14-23 08:00AM	Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update (PR Newswire)
Jun-28-23 07:00AM	Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis (PR Newswire) -5.37%
Jun-26-23 07:00AM	Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023 (PR Newswire) +28.00%
Jun-21-23 07:00AM	Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 (PR Newswire) -13.22%
Jun-05-23 07:00AM	Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update (PR Newswire)
Jun-02-23 09:00AM	Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis (PR Newswire) +8.12%
May-24-23 07:00AM	Chemomab Therapeutics to Participate in Upcoming Scientific Conferences (PR Newswire)
May-11-23 06:00AM	Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update (PR Newswire)
Apr-26-23 07:00AM	Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference (PR Newswire)
Apr-19-23 07:00AM	Chemomab Therapeutics to Present at Upcoming Scientific Conferences (PR Newswire)
Apr-12-23 07:00AM	Chemomab Therapeutics to Discuss First Quarter 2023 Financial Results and Provide a Corporate Update (PR Newswire)
08:30AM	Loading…
Mar-29-23 08:30AM	Chemomab Therapeutics to Provide a Corporate Update on April 17, 2023 (PR Newswire)
Mar-17-23 07:00AM	Chemomab Therapeutics to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide a Business Update (PR Newswire)
Mar-06-23 07:00AM	Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference (PR Newswire)
Feb-21-23 07:00AM	Chemomab Announces FDA Clearance of Investigational New Drug Application for Phase 2 Clinical Trial of CM-101 in Patients with Systemic Sclerosis (PR Newswire) +16.84%
Jan-03-23 07:00AM	Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients (PR Newswire) -8.13%
Dec-21-22 07:00AM	Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PR Newswire)
Nov-30-22 07:00AM	Chemomab Announces Appointment of Mitchell L. Jones, MD, PhD as Vice President of Corporate Development & Strategy (PR Newswire)
Nov-11-22 06:00AM	Chemomab Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Nov-09-22 08:00AM	Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19 (PR Newswire)
Nov-01-22 07:00AM	Chemomab Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Business Update (PR Newswire)
Oct-28-22 07:00AM	Chemomab Therapeutics to Present at Upcoming Scientific Conferences (PR Newswire)
Aug-12-22 06:00AM	Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire) +7.24%
06:00AM	Chemomab Adds Highly Experienced Executives Further Strengthening Its R&D and Clinical Capabilities (PR Newswire)
Aug-01-22 07:00AM	Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update (PR Newswire)
Jun-27-22 08:00AM	Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis (PR Newswire)
Jun-21-22 07:00AM	Chemomab Therapeutics Appoints Jill M. Quigley, JD, to Its Board of Directors (PR Newswire) +5.42%
Jun-09-22 09:00AM	Chemomab Therapeutics to Present at June Investor and Scientific Conferences (PR Newswire)
Jun-02-22 07:00AM	Data Supporting Role of Chemomab's Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022 (PR Newswire)
May-18-22 07:00AM	Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference (PR Newswire)
May-12-22 06:00AM	Chemomab Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
May-04-22 07:00AM	Chemomab Therapeutics to Report First Quarter 2022 Financial Results and Provide a Business Update (PR Newswire)
Mar-23-22 07:00AM	Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit (PR Newswire)
Mar-14-22 08:00AM	Chemomab Reports on Two Scientific Presentations that Support the Potential Therapeutic Utility of CM-101 in Systemic Sclerosis (PR Newswire) -5.48%
Mar-09-22 06:00AM	Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update (PR Newswire)
Mar-02-22 08:00AM	Chemomab Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update (PR Newswire)
Feb-10-22 08:00AM	Chemomab Therapeutics to Present at Aegis Virtual Conference (PR Newswire)
Jan-04-22 07:00AM	Chemomab Therapeutics Names Jack Lawler Vice President of Global Clinical Development Operations (PR Newswire)
Dec-20-21 08:00AM	Chemomab to Participate in LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference (PR Newswire)
Dec-16-21 04:05PM	Chemomab Therapeutics Announces Expected Appointment of Dale R. Pfost as Chairman of the Board (PR Newswire)
Dec-03-21 08:00AM	Chemomab Therapeutics Names David M. Weiner, MD as Interim Chief Medical Officer (PR Newswire) -11.27%
Dec-02-21 07:00AM	Chemomab Announces FDA Clearance of Its IND Application for CM-101, a First-In-Class CCL24 Neutralizing Antibody for the Treatment of Primary Sclerosing Cholangitis (PR Newswire)
Nov-23-21 05:34AM	Insiders who purchased Chemomab Therapeutics Ltd. (NASDAQ:CMMB) earlier this year lose an additional US$78k as the stock sinks to US$8.99 (Simply Wall St.) -5.67%
Nov-12-21 07:00AM	Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update (PR Newswire)
Nov-10-21 07:00AM	Chemomab Announces Poster Presentation at AASLD's The Liver Meeting® 2021 (PR Newswire) -5.01%
Nov-09-21 07:00AM	Chemomab to Present at Stifel 2021 Virtual Healthcare Conference (PR Newswire)
Nov-08-21 07:00AM	Chemomab Therapeutics Names Donald R. Marvin Chief Financial Officer, Executive Vice President and Chief Operating Officer (PR Newswire)
Oct-26-21 08:53AM	Chemomab Therapeutics Hosting Key Opinion Leader Webinar on Systemic Sclerosis (PR Newswire)
Oct-15-21 11:42AM	Wonderland: Miami to Showcase the Business of Psychedelic Medicine (Exec Edge)
Sep-27-21 07:00AM	Chemomab Therapeutics Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascular Damage Associated with Systemic Sclerosis (PR Newswire)
Sep-02-21 07:00AM	Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer (PR Newswire)
Sep-01-21 07:18AM	Chemomab to Participate in Upcoming September Investor Conferences (PR Newswire)
Aug-13-21 08:00AM	Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update (PR Newswire) -8.23%
Jun-23-21 08:30AM	Chemomab Therapeutics and AGC Biologics Expand Their Partnership to Manufacture CM-101 for Phase II/III (PR Newswire)
08:30AM	Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III (GlobeNewswire)
Jun-17-21 02:44AM	What You Need To Know About Chemomab Therapeutics Ltd.'s (NASDAQ:CMMB) Investor Composition (Simply Wall St.)
Jun-10-21 07:00AM	Chemomab Announces Poster Presentation at the International Liver Congress 2021 (EASL) (PR Newswire)
May-17-21 08:30PM	Buy These 2 Stocks Before They Double, Says Oppenheimer (TipRanks)
May-13-21 09:25AM	Chemomab Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update (PR Newswire)
May-12-21 07:00AM	Chemomab to Present at Oppenheimer's Virtual Rare and Orphan Disease Summit (PR Newswire)
Apr-26-21 06:30AM	Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH) (PR Newswire)
Mar-29-21 09:00AM	Chemomab Announces Four New Appointments to the Board of Directors and Completion of PIPE Financing (PR Newswire) -5.48%
Mar-22-21 07:00AM	Genesis Prize Co-Founder Stan Polovets Steps Down as Chairman of Anchiano Therapeutics after Company Posts 630% Return in 12 Months (PR Newswire) -9.02%

Chemomab Therapeutics Ltd. operates as a clinical-stage biotech company. It discovers and develops therapeutics for conditions with unmet need that involve Inflammation and fibrosis. The company was founded by Adi Mor on September 22, 2011 and is headquartered in Tel Aviv, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CMMB

Chemomab Therapeutics Ltd ADR

Upgrade your FINVIZ experience